ArticleGene therapy2004
A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma.
Article in Gene therapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 51 citations in OpenAlex.
- Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures.Molecular therapy oncolytics · 2022Article
- Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.Cancer gene therapy · 2021Review
- Oncolytic immunotherapy: where are we clinically?Scientifica · 2014Review
- A tumor-stroma targeted oncolytic adenovirus replicated in human ovary cancer samples and inhibited growth of disseminated solid tumors in mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer.PloS one · 2011Article
- Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).Experimental and therapeutic medicine · 2010Article
- Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma.Cancer science · 2010Article
- Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment.Gene therapy · 2009Article
- Tetracycline-inducible promoter-based conditionally replicative adenoviruses for the control of viral replication.Cancer gene therapy · 2009Article
- Human dendritic cells infected with an adenoviral vector suppress proliferation of autologous and allogeneic T cells.Immunology · 2008Article
- Systemic therapy for cervical cancer with potentially regulatable oncolytic adenoviruses.PloS one · 2008Article
- A three-dimensional assay for measurement of viral-induced oncolysis.Cancer gene therapy · 2007Article
- Advanced generation adenoviral virotherapy agents embody enhanced potency based upon CAR-independent tropism.Clinical cancer research : an official journal of the American Association for Cancer Research · 2006Review
- Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice.Gene therapy · 2006Article
- Recent progress in the battle between oncolytic viruses and tumours.Nature reviews. Cancer · 2005Review
- Review
- Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors.Cancer gene therapy · 2005Article
- Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model system.Breast cancer research : BCR · 2005Article
- Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells.Gene therapy · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Conditionally replicating adenoviruses (CRADs) take advantage of tumor-specific characteristics for preferential replication and subsequent oncolysis of cancer cells. The antitumor effect is determined by the capability to infect tumor cells. Here, we used RGDCRADcox-2R, which features the cyclooxygenase-2 promoter for replication control and an integrin binding RGD-4C motif for enhanced infectivity of ovarian cancer cells. RGDCRADcox-2R replicated in and killed human ovarian cancer cells effectively, while the replication in nonmalignant cells was low. Importantly, the therapeutic efficacy, as evaluated in an orthotopic model of peritoneally disseminated ovarian cancer, was significantly improved and toxicity was lower than with a wild-type virus. Thus, this CRAD could be tested for treatment of ovarian cancer in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.